• Katharina Vezyroglou, Katrin Mehler, Angela Kribs, Ingrid Becker, Kristina Langhammer, Bernhard Roth, and Christoph Hünseler.
• Department of Neonatology and Pediatric Intensive Care Medicine, Children's Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany, katharina.vezyroglou@uk-koeln.de.
• Eur. J. Pediatr. 2015 Jul 1; 174 (7): 867-74.

UnlabelledTo investigate whether orally applied glucose reduces pain response during oropharyngeal suctioning in preterm infants with a birth weight >1500 g, we conducted a randomized, double-blind, placebo-controlled cross-over trial on 32 preterm infants undergoing oropharyngeal suctioning while on nasal continuous positive airway pressure (CPAP). The Premature Infant Pain Profile (PIPP) score was assessed and compared in a cross-over design to investigate whether there was a significant difference in the patients' pain response. The mean PIPP score during oropharyngeal suctioning after placebo was 8.6 (KI 7.8-9.4). After glucose administration, the mean PIPP score was 8.0 (KI 7.1-8.9). Comparison of the treatment effects reached no statistic significance (p = 0.23). During the oral study drug administration during nasal CPAP, we observed 47 adverse events, but none necessitated therapeutic intervention and none was classified as serious.ConclusionIn our study, late preterm infants in the first days of life did not benefit significantly from analgesia with glucose during oropharyngeal suctioning. The oral administration of glucose under nasal CPAP led to no serious adverse events.

26 keywords...

hide…